癌ワクチンの世界市場：成長、動向、および予測（2019年～2024年）

世界の癌ワクチン市場は、2019年から2024年の間に16.7％のCAGRで成長する見通しです。

当レポートは世界の癌ワクチン市場について調査しており、市場機会や動向、成長および阻害要因、技術・治療方法・用途・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

• 調査成果
• 調査の仮定
• 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

• 市場概況
• 成長要因
• 阻害要因
• ポーターのファイブフォース分析
  • 新規参入の脅威
  • バイヤー/消費者の交渉力
  • サプライヤーの交渉力
  • 代替製品の脅威
  • 業界内の競争

第5章 市場セグメント

• 技術別
  • 組換え癌ワクチン
  • 全細胞癌ワクチン
  • ウイルスベクター・DNA癌ワクチン
  • その他（樹状細胞、抗原など）
• 治療法別
  • 予防ワクチン
  • 治療ワクチン
• 用途別
  • 前立腺癌
  • 子宮頸癌
  • その他（肝臓癌、皮膚癌など）
• 地域別
  • 北米
  • 欧州
  • アジア太平洋地域
  • 中東・アフリカ地域
  • 南米

第6章 競合情勢

• 企業プロファイル
  • Aduro BioTech, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb
  • Dendreon
  • GlaxoSmithKline
  • Merck & Co., Inc.
  • OSE Immunotherapeutics
  • Sanofi

第7章 市場機会および将来動向

Market Overview

Global Cancer Vaccines market is expected to witness a CAGR of 16.7% during the forecast period. Certain factors that are driving the market growth include the increasing number of cancer cases, rising investments and government funding in the development of cancer vaccines, and technological development in cancer vaccines.

The incidence of cancer is increasing every year and has been the major factor for the growth of the cancer vaccines market. Cancer damages the immune system, as cancer cells produce the self-antigen. The cancer vaccines play a vital role in the maintenance of the immune system, as they are considered the biological response modifiers. These cancer vaccines target the infectious agents that may cause cancer through the production of the antibodies. Cancer vaccines are considered as a new therapy and are not popular compared to the other alternative therapeutic drugs. However, cancer vaccines have shown great potential in both preventive and therapeutic ways. Also, healthcare physicians are looking for the alternative therapies due to the huge burden of cancer cases and side effects of the present therapies, the market of cancer vaccine are expected to grow with a high growth rate during the forecast period.

However, in the expanding market for medical therapies, there are stringent regulatory policies in place to ensure the safety of therapies. The FDA review process takes twice as much as time as European regulatory commissions' review bodies. Hence, citizens from countries where the review process is shorter benefit more than countries with longer review processes and stringent regulations. The presence of stringent regulations is hindering the growth of this market.

Scope of the Report

Cancer vaccines are defined as the vaccines developed to prevent or treat existing cancer by strengthening the body's natural immune response system against cancer. These cancer vaccines belong to a class of substances known as biological response modifiers. These modifiers work by stimulating or restoring the immune system's ability to fight against diseases.

Key Market Trends

Preventive Vaccines are Expected to Hold Significant Market Share in the Treatment Method Segment

Preventive vaccines or prophylactic vaccines are the vaccines intended to prevent cancer in healthy people. These vaccines work by preventing infectious agents that cause or contribute to the development of cancer. These vaccines are similar to traditional vaccines that help prevent infectious diseases, such as polio and measles, by protecting the body against infections. Most of the preventive vaccines stimulate the production of antibodies, which bind to specific targeted microbes and block their ability to cause infection.

North America Dominates the Market and is Expected to do Same in the Forecast Period

This is due to the high prevalence of cancer, along with developed healthcare infrastructure in the region. According to the National Cancer Institute, preventive vaccines were approved to treat cancers by the use of vaccines, namely Human papillomavirus (HPV) vaccines and the Hepatitis B virus (HBV). However, there are many other vaccines that are approved by the FDA for the prevention of cancer. In April 2010, the first cancer treatment vaccine, called sipuleucel-T (Provenge), was approved by the FDA. This vaccine was approved for use in men with metastatic prostate cancer. It was designed to stimulate an immune response to prostatic acid phosphatase (PAP), which is an antigen found in most prostate cancer cells. Moreover, in October 2015, the first oncolytic virus therapy, called talimogene laherparepvec (T-VEC, or Imlygic), was also approved by the FDA. This vaccine is used for the treatment of metastatic melanoma that cannot be surgically removed.

Competitive Landscape

The global Cancer Vaccines market is highly competitive and consists of a few major players. Companies like Aduro BioTech, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Dendreon, GlaxoSmithKline, Merck & Co., Inc., OSE Immunotherapeutics, Sanofi, Welland Medical Ltd, among others, hold the substantial market share in the Cancer Vaccines market.

Reasons to Purchase this report:

• The market estimate (ME) sheet in Excel format
• Report customization as per the client's requirements
• 3 months of analyst support

Table of Contents

1 INTRODUCTION

• 1.1 Study Deliverables
• 1.2 Study Assumptions
• 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Number of Cancer Cases
  • 4.2.2 Rising Investments and Government Funding in the Development of Cancer Vaccines
  • 4.2.3 Technological Developments in Cancer Vaccines
• 4.3 Market Restraints
  • 4.3.1 Stringent Regulatory Guidelines and Longer Timelines Required for Manufacturing Process
  • 4.3.2 Presence of Alternative Therapies
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 Technology
  • 5.1.1 Recombinant Cancer Vaccines
  • 5.1.2 Whole Cell Cancer Vaccines
  • 5.1.3 Viral Vector and DNA Cancer Vaccines
  • 5.1.4 Others (Dendritic Cells, Antigen etc.)
• 5.2 Treatment Method
  • 5.2.1 Preventive Vaccine
  • 5.2.2 Therapeutic Vaccine
• 5.3 Application
  • 5.3.1 Prostate Cancer
  • 5.3.2 Cervical Cancer
  • 5.3.3 Others (Liver, Skin etc.)
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 US
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 UK
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Aduro BioTech, Inc.
  • 6.1.2 Astellas Pharma, Inc.
  • 6.1.3 AstraZeneca PLC
  • 6.1.4 Bristol-Myers Squibb
  • 6.1.5 Dendreon
  • 6.1.6 GlaxoSmithKline
  • 6.1.7 Merck & Co., Inc.
  • 6.1.8 OSE Immunotherapeutics
  • 6.1.9 Sanofi

7 MARKET OPPORTUNITIES AND FUTURE TRENDS